Kura Oncology (KURA) Gross Profit (2025 - 2026)

Kura Oncology's (KURA) quarterly Gross Profit came in at $18.0 million in Q1 2026, up 27.61% year-on-year from $14.1 million in Q1 2025, and up 27.61% on a QoQ basis from $14.1 million in Q1 2025.

Kura Oncology (KURA) Gross Profit (2025 - 2026) Analysis & Trends

Kura Oncology (KURA) has 2 years of Gross Profit data on file, last reported at $18.0 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Kura Oncology 928.19 Mn 928.19 Mn 18.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 18.00 Mn
Mar 31, 2026 18.00 Mn
Mar 31, 2025 14.11 Mn
Mar 31, 2025 14.11 Mn